Merit Medical(US:MMSI)2024-04-30 21:03Financial Performance - Q1 2024 - Merit Medical reported revenue of $323508 thousand for Q1 2024, an increase of 87% compared to $297565 thousand in Q1 2023[8] - On a constant currency basis, revenue increased by 93% to $325200 thousand[30] - Organic constant currency revenue grew by 70% to $318472 thousand, excluding revenue from certain acquisitions[30] - GAAP net income was $28240 thousand ($048 per share) compared to $20703 thousand ($036 per share) in Q1 2023, representing a 355% increase in EPS[56] - Non-GAAP net income increased by 195% to $44828 thousand ($077 per share) from $37515 thousand ($064 per share) in Q1 2023[32, 56] Regional Performance - Q1 2024 - US revenue increased by 86% to $186094 thousand from $171360 thousand in Q1 2023[8] - APAC revenue increased by 93% to $62865 thousand from $57536 thousand in Q1 2023[8] - EMEA revenue increased by 51% to $61006 thousand from $58053 thousand in Q1 2023[8] - Rest of World revenue increased significantly by 276% to $13543 thousand from $10616 thousand in Q1 2023[8] - Total International revenue increased by 89% to $137414 thousand from $126205 thousand in Q1 2023[8] 2024 Financial Guidance - The company reaffirmed its 2024 net sales guidance, projecting a 43% to 54% increase from the prior year, equating to $1312 - $1325 billion[17, 38] - The estimated impact of foreign currency exchange rate fluctuations is 05%[17] - The company anticipates non-GAAP earnings per share of $328 - $335, representing a 9% - 11% increase[38]